熱門資訊> 正文

Terns Pharmaceuticals提议4亿美元的股权发行

2025-12-09 19:37

Terns Pharmaceuticals, Inc.(TERN) 0

Terns Pharmaceuticals (TERN) has launched a proposed $400M public offering of common stock and pre-funded warrants.
The company also plans to give underwriters a 30-day option to buy up to an additional $60M in shares. Terns plans to use the net proceeds from the proposed offering to fund research, clinical trials, development, and manufacturing of key product candidates, including TERN-701, and for working capital and general corporate purposes.
TERN -4.28% premarket at $38.51.

More on Terns Pharmaceuticals

Terns Pharmaceuticals, Inc. (TERN) Discusses Efficacy and Safety Data Update for TERN-701 in Chronic Myeloid Leukemia Transcript
Terns Pharmaceuticals: GLP-1 Obesity Drug Cut Warrants Downgrade To 'Hold' Rating
Terns Pharmaceuticals: Valued As If It Can't Win
Terns Pharmaceuticals GAAP EPS of -$0.27
Terns falls as phase 2 data on oral GLP-1 obesity asset disappoints

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。